The Comprehensive in Vitro Proarrhythmia Assay (CiPA) paradigm was initiated by a Steering Team following a meeting on July 27, 2013. The Steering Team is comprised of partners from the US FDA, HESI, CSRC, SPS, Japan NIH, PMDA, EMA and Health Canada. The CiPA work streams were developed by the Steering Team include: In Silico, Myocyte, Ion Channel, and Clinical Translation working groups. Additional organizations and individual scientists are contributing to the CiPA efforts via the work streams. Participation in any of the CIPA working groups or studies does not constitute endorsement from the CiPA Steering Team or other participating members of the consortia.

CiPA working groups are conducting studies, generating data and developing written materials to help guide the CiPA initiative. The working groups operate in precompetitive space where studies are collectively designed with the best possible science in mind and without bias toward any vendors, cell providers, contract research organizations (CROs) or instrument manufacturers.

Any protocols developed are generalized core protocols focused on minimum endpoints necessary to meet the needs of CiPA. The goal of the working groups’ studies is not to select any one platform or cell provider, but rather to determine minimum endpoints, reproducibility and validity of all assays for the purpose of CiPA, as endorsed by the CiPA Steering Team.

There is no final CiPA paradigm or protocol, and new guidelines have yet to be written or accepted by any international regulatory body. The initiative continues to evolve as new data are gathered and as such, it is anticipated the protocols will continue to evolve as well. Updates related to the progress of the CiPA initiative will be posted to the CiPA website: https://www.ilsiextra.org/hesi/science/cardiac/cipa.

A CiPA logo has been created for the project. Use of the CiPA logo is encouraged for all partners. However, use of the CiPA name or logo does not constitute endorsement from the CiPA Steering Team or other participating members of the consortia.